1-2 of 2
Joe De Keizer
Close
Sort by
Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Arthur Bobin, Salomon Manier, Joe De Keizer, Cyrille Hulin, Lionel Karlin, Denis Caillot, Clara Mariette, Carla Araujo, Bertrand Arnulf, Benoit Bareau, Karim Belhadj Merzoug, Lotfi Benboubker, Thorsten Braun, Claire Calmettes, Olivier Decaux, Mamoun Dib, Helene Demarquette, Pierre Feugier, Cécile Sonntag, Arnaud Jaccard, Pascal Lenain, Margaret Macro, Valentine Richez, Mourad Tiab, Laure Vincent, Hacene Zerazhi, Marie-Odile Petillon, Cyrille Touzeau, Aurore Perrot, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6724.
https://doi.org/10.1182/blood-2023-186599
Published: 2023
Journal Articles

Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML

Frederic Millot, Joe De Keizer, Markus Metzler, Meinolf Suttorp, Petr Sedlacek, Maaike Luesink, Frankie WT Cheng, Krzysztof Kalwak, Birgitte Lausen, Gordana Jakovljevic, Barbara De Moerloose, Michael Dworzak, Marina Borisevich, Julia Yajima, Mirella Ampatzidou, Roula Farah, Emilia Kaiserova, Adalet Meral Günes, Andre Baruchel
Journal: Blood
Blood (2023) 142 (Supplement 1): 448.
https://doi.org/10.1182/blood-2023-173810
Published: 2023